Meningococcal antigen in diagnosis and treatment of group A meningococcal infections

Am J Med. 1975 Jun;58(6):823-8. doi: 10.1016/0002-9343(75)90638-5.

Abstract

Meningococcal antigen was measured by countercurrent immunoelectrophoresis in the blood and cerebrospinal fluid of 200 patients with group A meningococcal meningitis. Antigen was detected in the blood of 27 (13.5 per cent) patients. These patients had a worse prognosis and a higher incidence of allergic complications, such as arthritis and vasculitis, about 5 days after the start of antibiotic treatment. Antigen was found in the CSF of 129 (67.5 per cent) patients); antigen often persisted in the cerebrospinal fluid despite antibiotic treatment before admission. A combination of immunoelectrophoresis and routine bacteriologic study was used in the diagnosis of 162 (84.8 per cent) patients with meningococcal meningitis. High levels of antigen and a slow antigen disappearance were associated with neurologic damage. The antigen is stable and may be detected from specimens of cerebrospinal fluid dried on filter paper.

Publication types

  • Clinical Trial

MeSH terms

  • Antigens, Bacterial* / analysis
  • Antigens, Bacterial* / cerebrospinal fluid
  • Chloramphenicol / therapeutic use
  • Clinical Trials as Topic
  • Humans
  • Immunoelectrophoresis
  • Length of Stay
  • Meningococcal Infections / diagnosis
  • Meningococcal Infections / drug therapy
  • Meningococcal Infections / immunology*
  • Penicillins / therapeutic use
  • Prognosis
  • Sulfonamides / therapeutic use

Substances

  • Antigens, Bacterial
  • Penicillins
  • Sulfonamides
  • Chloramphenicol